These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 15842581)

  • 41. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.
    Boza C; Riquelme A; Ibañez L; Duarte I; Norero E; Viviani P; Soza A; Fernandez JI; Raddatz A; Guzman S; Arrese M
    Obes Surg; 2005 Sep; 15(8):1148-53. PubMed ID: 16197788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients.
    Shalhub S; Parsee A; Gallagher SF; Haines KL; Willkomm C; Brantley SG; Pinkas H; Saff-Koche L; Murr MM
    Obes Surg; 2004 Jan; 14(1):54-9. PubMed ID: 14980034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease.
    Nobili V; Manco M; Devito R; Ciampalini P; Piemonte F; Marcellini M
    Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1553-61. PubMed ID: 17206944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
    Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA
    Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis.
    Charatcharoenwitthaya P; Levy C; Angulo P; Keach J; Jorgensen R; Lindor KD
    Liver Int; 2007 Mar; 27(2):220-6. PubMed ID: 17311617
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.
    Kugelmas M; Hill DB; Vivian B; Marsano L; McClain CJ
    Hepatology; 2003 Aug; 38(2):413-9. PubMed ID: 12883485
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
    Georgescu EF; Georgescu M
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):39-46. PubMed ID: 17410287
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial.
    Nair S; Diehl AM; Wiseman M; Farr GH; Perrillo RP
    Aliment Pharmacol Ther; 2004 Jul; 20(1):23-8. PubMed ID: 15225167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity.
    Stratopoulos C; Papakonstantinou A; Terzis I; Spiliadi C; Dimitriades G; Komesidou V; Kitsanta P; Argyrakos T; Hadjiyannakis E
    Obes Surg; 2005 Sep; 15(8):1154-60. PubMed ID: 16197789
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.
    Kang H; Greenson JK; Omo JT; Chao C; Peterman D; Anderson L; Foess-Wood L; Sherbondy MA; Conjeevaram HS
    Am J Gastroenterol; 2006 Oct; 101(10):2247-53. PubMed ID: 17032189
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.
    Dixon JB; Bhathal PS; Hughes NR; O'Brien PE
    Hepatology; 2004 Jun; 39(6):1647-54. PubMed ID: 15185306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
    Ratziu V; Giral P; Jacqueminet S; Charlotte F; Hartemann-Heurtier A; Serfaty L; Podevin P; Lacorte JM; Bernhardt C; Bruckert E; Grimaldi A; Poynard T;
    Gastroenterology; 2008 Jul; 135(1):100-10. PubMed ID: 18503774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
    Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
    Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery.
    Pirvulescu I; Gheorghe L; Csiki I; Becheanu G; Dumbravă M; Fica S; Martin S; Sarbu A; Gheorghe C; Diculescu M; Copăescu C
    Chirurgia (Bucur); 2012; 107(6):772-9. PubMed ID: 23294957
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and pathological differences between alcoholic hepatitis and non-alcoholic steatohepatitis.
    Sugimoto M; Sadamoto T; Nonaka H
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2003 Feb; 38(1):34-45. PubMed ID: 12687723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum leptin levels in patients with nonalcoholic steatohepatitis.
    Uygun A; Kadayifci A; Yesilova Z; Erdil A; Yaman H; Saka M; Deveci MS; Bagci S; Gulsen M; Karaeren N; Dagalp K
    Am J Gastroenterol; 2000 Dec; 95(12):3584-9. PubMed ID: 11151896
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-alcoholic steatohepatitis in type 2 diabetes mellitus.
    Gupte P; Amarapurkar D; Agal S; Baijal R; Kulshrestha P; Pramanik S; Patel N; Madan A; Amarapurkar A; Hafeezunnisa
    J Gastroenterol Hepatol; 2004 Aug; 19(8):854-8. PubMed ID: 15242486
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss.
    Luyckx FH; Lefebvre PJ; Scheen AJ
    Diabetes Metab; 2000 Apr; 26(2):98-106. PubMed ID: 10804323
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model.
    Yalniz M; Bahcecioglu IH; Kuzu N; Poyrazoglu OK; Bulmus O; Celebi S; Ustundag B; Ozercan IH; Sahin K
    J Gastroenterol Hepatol; 2007 Nov; 22(11):2009-14. PubMed ID: 17914984
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence of metabolic syndrome in non-diabetic and non-cirrhotic patients with non-alcoholic steatohepatitis.
    Amarapurkar DN; Patel ND
    Trop Gastroenterol; 2004; 25(3):125-9. PubMed ID: 15682659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.